Swedencare Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Swedencare verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 23.3%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 8.9%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 53%. Die Eigenkapitalrendite von Swedencare beträgt 1% und die Nettomargen betragen 3.1%.

Wichtige Informationen

23.3%

Wachstumsrate der Gewinne

7.3%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	30.5%
Wachstumsrate der Einnahmen	53.0%
Eigenkapitalrendite	1.0%
Netto-Marge	3.1%
Nächste Ertragsaktualisierung	23 Oct 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Analysts Just Published A Bright New Outlook For Swedencare AB (publ)'s (STO:SECARE)

Feb 16

Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?

Dec 28

A Look At The Fair Value Of Swedencare AB (publ) (STO:SECARE)

Dec 06

Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet

Oct 24

With EPS Growth And More, Swedencare (STO:SECARE) Is Interesting

Sep 12

Calculating The Fair Value Of Swedencare AB (publ) (STO:SECARE)

Aug 19

Broker Revenue Forecasts For Swedencare AB (publ) (STO:SECARE) Are Surging Higher

Jul 28

Industry Analysts Just Made A Substantial Upgrade To Their Swedencare AB (publ) (STO:SECARE) Revenue Forecasts

Jul 01

Swedencare (STO:SECARE) Has A Rock Solid Balance Sheet

Jun 29

Aufschlüsselung der Einnahmen und Ausgaben

Wie Swedencare Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OM:SECARE Einnahmen, Ausgaben und Erträge (SEK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Jun 24	2,472	76	859
31 Mar 24	2,414	72	830
31 Dec 23	2,338	59	803
30 Sep 23	2,199	87	736
30 Jun 23	2,085	53	726
31 Mar 23	1,987	97	690
31 Dec 22	1,843	95	640
30 Sep 22	1,600	98	547
30 Jun 22	1,335	105	456
31 Mar 22	1,019	60	345
31 Dec 21	773	55	259
30 Sep 21	618	40	205
30 Jun 21	465	44	146
31 Mar 21	337	34	114
31 Dec 20	240	33	87
30 Sep 20	174	34	72
30 Jun 20	136	28	61
31 Mar 20	134	30	58
31 Dec 19	127	30	54
30 Sep 19	121	30	50
30 Jun 19	113	28	48
31 Mar 19	108	27	47
31 Dec 18	99	23	44
30 Sep 18	94	23	41
30 Jun 18	92	20	42
31 Mar 18	85	17	41
31 Dec 17	86	17	40
30 Sep 17	78	12	39
30 Jun 17	70	11	35
31 Mar 17	63	12	31
31 Dec 16	54	10	28
30 Sep 16	43	9	23
30 Jun 16	37	8	19
31 Mar 16	34	8	15
31 Dec 15	27	7	10
31 Dec 14	24	4	9
31 Dec 13	18	0	9

Qualität der Erträge: SECARE hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: SECAREDie aktuellen Gewinnspannen (3.1%) sind höher als im letzten Jahr (2.6%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: SECAREIn den letzten 5 Jahren sind die Einnahmen von 25% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: SECAREDas Gewinnwachstum des Unternehmens im letzten Jahr (43.3%) übertrifft seinen 5-Jahres-Durchschnitt (23.3% pro Jahr).

Erträge im Vergleich zur Industrie: SECARE Das Gewinnwachstum im vergangenen Jahr (43.3%) übertraf das der Branche Pharmaceuticals 4.5% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: SECAREDie Eigenkapitalrendite des Unternehmens (1%) wird als niedrig angesehen.

Swedencare Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Swedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Swedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Swedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025

Chief Executive Officer recently bought kr874k worth of stock

Consensus EPS estimates fall by 22%

Chief Executive Officer recently bought kr941k worth of stock

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Swedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025

Upcoming dividend of kr0.23 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Swedencare AB (Publ) Announces Nomination Committee Appointments

Price target increased by 8.7% to kr50.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Swedencare AB (publ), Annual General Meeting, Apr 25, 2024

New minor risk - Share price stability

Price target decreased by 7.1% to kr46.00

Price target increased by 10% to kr49.50

Consensus EPS estimates fall by 31%, revenue upgraded

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: kr0.10 (vs kr0.49 in 2Q 2022)

Investor sentiment improves as stock rises 15%

Chief Executive Officer recently bought kr472k worth of stock

Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion

Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Price target decreased by 12% to kr42.00

First quarter 2023 earnings: EPS misses analyst expectations

Does Swedencare (STO:SECARE) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 22%

Upcoming dividend of kr0.22 per share at 0.8% yield

Chief Executive Officer recently bought kr241k worth of stock

Chief Executive Officer recently bought kr241k worth of stock

Consensus EPS estimates fall by 27%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 14% to kr47.25

Swedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

Swedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023

Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Investor sentiment improved over the past week

Chief Executive Officer recently bought kr315k worth of stock

Chief Executive Officer recently bought kr328k worth of stock

Swedencare (STO:SECARE) Seems To Use Debt Quite Sensibly

Swedencare AB (publ), Annual General Meeting, Apr 28, 2023

Investor sentiment deteriorated over the past week

Here's Why We Think Swedencare (STO:SECARE) Might Deserve Your Attention Today

Price target decreased to kr75.00

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

With EPS Growth And More, Swedencare (STO:SECARE) Makes An Interesting Case

Consensus forecasts updated

Price target decreased to kr120

Second quarter 2022 earnings released: EPS: kr0.49 (vs kr0.31 in 2Q 2021)

Swedencare (STO:SECARE) Has A Pretty Healthy Balance Sheet

High number of new directors

Chief Executive Officer recently bought kr162k worth of stock

Consensus forecasts updated

Price target decreased to kr165

Less than half of directors are independent

Upcoming dividend of kr0.20 per share

Should You Be Adding Swedencare (STO:SECARE) To Your Watchlist Today?

Swedencare AB (publ) Proposes Dividend, Payable on 5 May 2022

Price target decreased to kr165

Swedencare AB (Publ) Proposes Dividend for 2021

Analysts Just Published A Bright New Outlook For Swedencare AB (publ)'s (STO:SECARE)

Now 23% undervalued after recent price drop

Swedencare AB (publ) (OM:SECARE) agreed to acquire The Garmon Corporation for approximately $470 million.

Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?